20/01/2026
During „TOXINS 2026“, the 8th international Conference of the International Neurotoxin Association in Madrid,I had the great honor to be elected on the board of directors as Director-at-large. It makes me very happy and proud that my continuous contributions to the field of Botulinumtoxin research and application lead to this prestigious and influencial position. As a collaborator on the clinical approval trial for Botox in hyperhidrosis in 1995 I had my first early contact with the clinical application of this life-changeing drug. In the following decades,I have become an expert in the broad range of aesthetic indications, have published more than 20 scientific and clinical publications on Botulinumtoxin,have served as a principal investigator on trial for a range of different neuromodulators,and have trained and educated around the globe thousands of colleagues. The International Neurotoxin Association is a non-commercial society of academic researchers,basic scientists,clinical specialists,and pharmaceutical company researchers in the field of Botulinumtoxin. The mission of the society is to promote research on Botulinumtoxin, providing clinical education to specialists and clinicians, and to advocate for patients who can potentially benefit from Neuromodulator treatment. The board directors represent a broad range of clinical specialties that administer Botulinumtoxin, such as neurologists,pediatric neurologist,rehabilitation physicians, ENT specialists, and basic scientists. As a cosmetic dermatologist,I am the only representative for aesthetic application of Neuromodulator treatment. My mission for my upcoming years as Director is to strengthen the collaboration of the clinical disciplines,to further broaden the cross-disciplinary learning among physicians in the field of Botulinum treatment, and to ultimately elevate the standard of care for patients receiving Neuromodulators across all indications. The dates and location of the next TOXINS conference in 2028 will be announced soon